Drug Trial Radar · NCT00996164
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
Last checked: Nov 20, 2026Latest source record: May 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,090
Actual
Start
Oct 2009
Primary completion
Dec 2010
Study completion Feb 2011
Sponsor
- Lead sponsor
- Sprout Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
Conditions
- Sexual Dysfunctions, Psychological
Interventions
FlibanserinDrug
patients will be randomized to flibanserin or placebo in a double-blind manner
PlaceboDrug
patients will be randomized to flibanserin or placebo in a double-blind manner
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain.Time frame: 24 weeks
- Change From Baseline in the SSE Count From Baseline to 24 WeeksTime frame: 24 weeks
Locations
75 sites in 1 country. Site status is shown where the registry gives one.
511.147.01074 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
511.147.01046 Boehringer Ingelheim Investigational Site
Huntsville, Alabama
511.147.01042 Boehringer Ingelheim Investigational Site
Mobile, Alabama
511.147.01025 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
511.147.01073 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
511.147.01030 Boehringer Ingelheim Investigational Site
Encinitas, California
511.147.01028 Boehringer Ingelheim Investigational Site
Fair Oaks, California
511.147.01037 Boehringer Ingelheim Investigational Site
Irvine, California
511.147.01022 Boehringer Ingelheim Investigational Site
Sacramento, California
511.147.01035 Boehringer Ingelheim Investigational Site
San Diego, California
511.147.01052 Boehringer Ingelheim Investigational Site
San Diego, California
511.147.01016 Boehringer Ingelheim Investigational Site
Torrance, California
511.147.01021 Boehringer Ingelheim Investigational Site
Vista, California
511.147.01051 Boehringer Ingelheim Investigational Site
Westlake Village, California
511.147.01071 Boehringer Ingelheim Investigational Site
Denver, Colorado
511.147.01053 Boehringer Ingelheim Investigational Site
Farmington, Connecticut
511.147.01015 Boehringer Ingelheim Investigational Site
Groton, Connecticut
511.147.01041 Boehringer Ingelheim Investigational Site
New Britain, Connecticut
511.147.01064 Boehringer Ingelheim Investigational Site
Newark, Delaware
511.147.01062 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia
511.147.01003 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida
511.147.01056 Boehringer Ingelheim Investigational Site
Clearwater, Florida
511.147.01065 Boehringer Ingelheim Investigational Site
Daytona Beach, Florida
511.147.01020 Boehringer Ingelheim Investigational Site
Miami, Florida
511.147.01024 Boehringer Ingelheim Investigational Site
Miami, Florida
511.147.01070 Boehringer Ingelheim Investigational Site
New Port Richey, Florida
511.147.01043 Boehringer Ingelheim Investigational Site
Orlando, Florida
511.147.01019 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida
511.147.01061 Boehringer Ingelheim Investigational Site
Tampa, Florida
511.147.01066 Boehringer Ingelheim Investigational Site
Tampa, Florida
511.147.01001 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
511.147.01002 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
511.147.01009 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
511.147.01023 Boehringer Ingelheim Investigational Site
Atlanta, Georgia
511.147.01008 Boehringer Ingelheim Investigational Site
Sandy Springs, Georgia
511.147.01044 Boehringer Ingelheim Investigational Site
Chicago, Illinois
511.147.01034 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana
511.147.01067 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana
511.147.01013 Boehringer Ingelheim Investigational Site
Baltimore, Maryland
511.147.01031 Boehringer Ingelheim Investigational Site
Bingham Farms, Michigan
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.